Arif Hussain
Affiliations: | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
BiochemistryGoogle:
"Arif Hussain"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rifai S, Rifai A, Shi X, et al. (2025) Genomic and transcriptomic sequencing in prostate cancer. Current Opinion in Oncology |
| Boyle J, Yau J, Slade JL, et al. (2024) Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. OF1-OF9 |
| Pornour M, Jeon HY, Ryu H, et al. (2024) USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America. 121: e2403331121 |
| Boyle J, Yau J, Slade JL, et al. (2024) Neighborhood Disadvantage and Prostate Tumor RNA Expression of Stress-Related Genes. Jama Network Open. 7: e2421903 |
| Kango G, Malek R, Mannuel H, et al. (2024) Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology. Current Opinion in Oncology. 36: 195-201 |
| Jeon HY, Pornour M, Ryu H, et al. (2023) SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research |
| Loehr A, Hussain A, Patnaik A, et al. (2022) Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. European Urology |
| Adediran S, Wang L, Khan MA, et al. (2022) Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. Cancers. 14 |
| Hussain A, Jiang S, Varghese D, et al. (2022) Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. Bmc Cancer. 22: 304 |
| Vogelzang NJ, Beer TM, Gerritsen W, et al. (2022) Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Jama Oncology |